Walk into any supplement aisle or scroll through online stores and you will find urolithin A sold as gummies, softgels, and plain powder. The format you choose matters more than it might seem, because urolithin A is a fat-soluble compound that poses real absorption challenges. Getting enough of it into systemic circulation is not a given regardless of the dose printed on the label.
The honest starting point is that no published clinical trial has run a head-to-head comparison of UA gummies against softgels or powder in humans. What does exist is a growing body of pharmaceutical research examining how formulation choices shape urolithin A’s bioavailability and biological activity. This article draws on that science to give you a realistic picture of what each format offers and where the evidence runs out.
Key Takeaways
- No clinical trial has directly compared urolithin A gummies, softgels, and powder head to head; formulation quality within a format matters more than the format itself.
- Urolithin A is fat-soluble, so delivery formats that include a lipid vehicle or emulsifier offer a theoretical absorption advantage over plain aqueous matrices [6].
- Research on submicron emulsions and nanocarriers confirms that engineering the physical carrier around UA meaningfully improves its bioavailability and biological activity [4][5].
- Taking any oral UA supplement with a fat-containing meal is a reasonable practical step to support absorption.
- Look for manufacturers who publish formulation details or human pharmacokinetic data; the format label alone (gummy, softgel, powder) is insufficient to judge a product’s bioavailability.
What Urolithin A Is and How It Works in Cells
Urolithin A is a postbiotic compound produced when gut microbiota metabolize ellagitannins, polyphenols found in foods like pomegranates, walnuts, and certain berries. Because only a minority of people harbor the gut bacteria needed for efficient conversion, direct supplementation has become a practical route to raising UA levels.
Its primary studied mechanism is the activation of mitophagy, the cellular housekeeping process by which damaged or dysfunctional mitochondria are identified and recycled. Healthy mitochondrial turnover supports energy production, reduces oxidative stress, and is associated with muscle and metabolic health. A 2026 review summarizing translational research identifies mitophagy activation alongside anti-inflammatory and antioxidant pathways as central to urolithin A’s documented effects [6].
Understanding the mechanism matters here because mitophagy activation requires UA to reach cells at meaningful concentrations. That makes bioavailability not just a marketing talking point but a real biological question.
Why Formulation Matters: The Bioavailability Challenge
Urolithin A is lipophilic, meaning it dissolves in fats rather than water. This creates an absorption challenge: the aqueous environment of the gut limits how easily fat-soluble compounds cross intestinal membranes into the bloodstream. Bioavailability can vary substantially depending on the physical form of the supplement, the excipients used alongside the active ingredient, and whether the formulation includes any lipid vehicle or emulsifier [6].
Researchers have responded to this challenge by exploring advanced delivery systems. A 2025 study developed a submicron emulsion to carry urolithin A and demonstrated improved anti-inflammatory activity compared to unformulated UA, attributing the improvement to better particle dispersion and cellular uptake [4]. A 2026 study using a biomimetic nanocarrier reported enhanced gastrointestinal stability and antioxidant efficacy for urolithin A, noting that the carrier protected UA through the GI tract and improved its release at target sites [5].
These studies do not evaluate gummies, softgels, or commercial powders; they are proof-of-concept investigations. But they establish a clear principle: the physical carrier around urolithin A meaningfully shapes how much of it reaches circulation and how active it is once there.
Gummies: Convenience with Formulation Trade-offs
Gummies are water-based matrices, typically made with gelatin or pectin, sugar, and flavoring agents. They are convenient, palatable, and easy to take without water. For urolithin A specifically, the challenge is that a standard aqueous gummy base does not inherently solubilize a fat-soluble compound well. Unless a manufacturer incorporates an emulsifier, a lipid carrier, or a micellar formulation, the urolithin A in a gummy may simply be dispersed as fine particles rather than dissolved in a bioavailability-enhancing medium.
This does not mean gummies cannot work. A gummy from a manufacturer that uses emulsification technology may outperform a softgel from one that does not. The label alone rarely tells you which approach was used, and third-party pharmacokinetic data is the most reliable way to assess any specific product.
Gummies also tend to carry added sugars or sugar alcohols, which may be a consideration for people managing blood glucose. Some use pectin as an alternative to gelatin, which matters to vegetarians and vegans.
Softgels: A Lipid-Friendly Option
Softgel capsules are oil-filled, which gives them a structural advantage for fat-soluble compounds. The lipid interior can dissolve urolithin A and present it to the intestinal lining in a form closer to how dietary fats are naturally absorbed. For lipophilic molecules broadly, softgel delivery is a well-established pharmaceutical approach.
The caveat is that not every softgel contains an optimized lipid matrix. Some products use minimal carrier oil; others formulate with specific triglycerides or phospholipids chosen for their absorption-enhancing properties. As with gummies, the specific formulation rather than the format category determines real-world bioavailability.
Softgels are not suitable for vegans unless the capsule shell is plant-based (typically carrageenan or modified starch), and they can have a shorter shelf life in warm, humid conditions compared to dry powder or hard capsules.
Powder: Flexibility but No Built-In Solubility Solution
Powders offer the most flexibility in dosing and can be added to food or beverages. They typically contain fewer excipients than gummies, which appeals to consumers who prefer minimal additives. For plain urolithin A, a powder with no lipid carrier faces the same fat-solubility barrier as an unformulated gummy. The compound does not become water-soluble simply by being finely milled.
Some powdered products are micronized or nano-milled to reduce particle size, which increases surface area and can improve dissolution rate. Others include phospholipid complexes designed to enhance absorption. The key, again, is whether the manufacturer has addressed the lipophilicity challenge in the formulation itself.
Taking a plain UA powder alongside a meal containing dietary fat is one practical workaround, because dietary lipids can act as a natural absorption vehicle. This is not a guaranteed fix, but taking fat-soluble compounds with food is a pharmacologically reasonable general principle.
What Advanced Delivery Research Points Toward
The most consistent signal from the current delivery literature is that standard oral administration of urolithin A leaves meaningful absorption gains on the table, and that engineered formulations can recover some of those gains. Nanoparticle-based delivery has shown improved outcomes in preclinical models, with a 2019 study finding that oral nanoparticle urolithin A normalized cellular stress markers in a mouse model where standard delivery was less effective [1]. A 2025 study found that UA-laden nanoparticles provided cardioprotective effects in mice, in part through modulation of inflammatory pathways [3].
These are animal and cell-based studies and cannot be directly applied to claims about commercial supplements. But they reinforce that the gap between what urolithin A can do under optimized delivery conditions and what it does in a basic supplement matrix is not trivial. Consumers looking for the most bioavailable commercial product should seek out brands that publish formulation details or, ideally, human pharmacokinetic data.
Targeted delivery designs are also under active investigation. Research on inflammation-targeted UA delivery demonstrated that directing the compound toward specific tissues could amplify its effects [2]. While that work uses experimental nanocarriers rather than consumer supplements, it underscores that delivery engineering is a meaningful and evolving area for this compound.
🛒 Where to Buy Urolithin A
- Timeline Mitopure SoftgelsClinically studied
softgels, 500 mg/day — The clinically studied form (Amazentis); used in the human trials. - DoNotAge Pure Urolithin A
capsules, 250-500 mg — Popular longevity-brand generic, third-party tested. - ProHealth Longevity Urolithin A
capsules, 500 mg — Longevity-focused brand, often higher dose. - Double Wood Urolithin A
capsules, 250-500 mg — Budget-friendly, widely available, COA on request.
As an Amazon Associate we earn from qualifying purchases. Prices and availability vary; verify dose and third-party testing before buying.
A Note on the Evidence
The research cited in this article includes animal and in-vitro studies; findings from those models do not guarantee equivalent effects in humans. Urolithin A supplements are not approved to diagnose, treat, cure, or prevent any disease, and this article is not a substitute for personalized medical advice. Consult a qualified healthcare provider before starting any new supplement, particularly if you have an underlying health condition or take medications.
Frequently Asked Questions
Is there a clinical study comparing urolithin A gummies vs. softgels vs. powder?
No published clinical trial has run this direct comparison. Most delivery research on urolithin A examines novel formulations such as nanoparticles and emulsions rather than commercial product formats. A 2026 review discusses bioavailability broadly but does not compare consumer formats head-to-head [6].
Why does formulation matter so much for urolithin A absorption?
Urolithin A is fat-soluble and poorly water-soluble, which limits how readily it crosses intestinal membranes in a standard aqueous environment. Research on emulsion and nanocarrier delivery has shown that engineering the physical carrier around UA meaningfully improves its anti-inflammatory activity and gastrointestinal stability compared to unformulated compound [4][5].
Should I take urolithin A supplements with food?
Taking fat-soluble compounds alongside a meal containing dietary fat is a general pharmacological principle that may support absorption by providing a natural lipid vehicle. No study in the available evidence specifically tested food co-administration for commercial UA supplements, but the rationale is grounded in urolithin A’s documented lipophilic nature [6].
What is mitophagy and why is it relevant to urolithin A?
Mitophagy is the selective recycling of damaged mitochondria by the cell’s internal cleanup systems. Mitochondria that accumulate damage without being cleared contribute to reduced cellular energy output and increased oxidative stress. Urolithin A is studied for its ability to activate mitophagy pathways, and a 2026 review identifies this mechanism as central to its documented biological effects [6].
Are nanoparticle urolithin A products available as consumer supplements?
Nanoparticle formulations have shown improved outcomes in preclinical animal models [1][3], but these are experimental delivery systems studied in controlled research settings, not products currently available on the consumer market. Any commercial product claiming nanoparticle delivery should be evaluated carefully for supporting human data before that claim is relied upon.
Who should talk to a doctor before taking urolithin A supplements?
Anyone with a chronic health condition, people taking prescription medications, pregnant or breastfeeding individuals, and those managing kidney disease should consult a healthcare provider before adding urolithin A to their routine. The compound is under active investigation for its effects on cellular pathways that interact with multiple organ systems.
References
- Zou D et al. Oral delivery of nanoparticle urolithin A normalizes cellular stress and improves survival in mouse model of cisplatin-induced AKI. American journal of physiology. Renal physiology (2019). PMID 31532243
- Ghosh S et al. Inflammation-targeted delivery of Urolithin A mitigates chemical- and immune checkpoint inhibitor-induced colitis. Journal of nanobiotechnology (2024). PMID 39533380
- Wahab AT et al. Urolithin A-laden functional nanoparticles alleviate cisplatin-induced cardiotoxicity in mice by inhibiting inflammation-induced lymphangiogenesis. Free radical biology & medicine (2025). PMID 40516794
- Esposito E et al. Development of a submicron emulsion-based delivery system to improve the anti-inflammatory activity of urolithin A. Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques (2025). PMID 41280710
- Hu F et al. Biomimetic carboxymethyl β-glucan-ZIF-8 nanocarrier enhances structural stability, gastrointestinal release, and antioxidant efficacy of urolithin A via dectin-1-engaged mitophagy. Food research international (Ottawa, Ont.) (2026). PMID 41652714
- Yuan H et al. Urolithin A From Gut Metabolite to Therapeutic Agent: Bioavailability, Mechanisms, and Translational Insights. Journal of food science (2026). PMID 41866331
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.
